The design and synthesis of a new class of RTK/HDAC dual-targeted inhibitors

Molecules

Volumn 18, Issue 6, 2013, Pages 6491-6503

  Zhang, Xuan ^a   Su, Mingbo ^a   Chen, Yi ^b   Li, Jia ^b   Lu, Wei ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antitumor; Dual inhibitor; Histone deacetylase; Receptor tyrosine kinases; Synergistic effect

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE DEACETYLASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; HUMAN; IC 50; SYNTHESIS; ANTAGONISTS AND INHIBITORS; IC50;

DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84879641705     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18066491     Document Type: Article

References (29)

1. Kim, M.S.; Blake, M.; Baek, J.H.; Kohlhagen, G.; Pommier, Y.; Carrier, F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63, 7291-7300.
2. Bruzzese, F.; Rocco, M.; Castelli, S.; Di Gennaro, E.; Desideri, A.; Budillon, A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol. Cancer Ther. 2009, 8, 3075-3087.
3. Bevins, R.L.; Zimmer, S.G. It's about time: Scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res. 2005, 65, 6957-6966.
4. Ocker, M.; Alajati, A.; Ganslmayer, M.; Zopf, S.; Luders, M.; Neureiter, D.; Hahn, E.G.; Schuppan, D.; Herold, C. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J. Cancer Res. Clin. Oncol. 2005, 131, 385-394.
5. Sarcar, B.; Kahali, S.; Chinnaiyan, P. Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines. J. Neurooncol. 2010, 99, 201-207.
6. Dokmanovic, M.; Clarke, C.; Marks, P.A. Histone deacetylase inhibitors: Overview and perspectives. Mol. Cancer Res. 2007, 5, 981-989.
7. Lin, H.Y.; Chen, C.S.; Lin, S.P.; Weng, J.R.; Chen, C.S. Targeting histone deacetylase in cancer therapy. Med. Res. Rev. 2006, 26, 397-413.
8. Lee, M.J.; Kim, Y.S.; Kummar, S.; Giaccone, G.; Trepel, J.B. Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol. 2008, 20, 639-649.
9. Chen, C.S.; Weng, S.C.; Tseng, P.H.; Lin, H.P.; Chen, C.S. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 2005, 280, 38879-38887.
10. Cai, X.; Zhai, H.X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin- 6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. J. Med. Chem. 2010, 53, 2000-2009.
11. Lai, C.J.; Bao, R.; Tao, X.; Wang, J.; Atoyan, R.; Qu, H.; Wang, D.G.; Yin, L.; Samson, M.; Forrester, J.; et al. CUDC-101, a multitargeted inhibitor of histone deacetylase, Epidermal growth factor receptor, And human epidermal growth factor receptor 2, Exerts potent anticancer activity. Cancer Res. 2010, 70, 3647-3656.
12. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: A series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases. J. Med. Chem. 2009, 52, 2265-2279.
13. Mahboobi, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Novel chimeric histone deacetylase inhibitors: A series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity. J. Med. Chem. 2010, 53, 8546-8555.
14. Zhang, X.; Zhang, J.; Tong, L.; Luo, Y.; Su, M.; Zang, Y.; Li, J.; Lu, W.; Chen, Y., The discovery of colchicine-SAHA hybrids as a new class of antitumor agents. Bioorg. Med. Chem. 2013, 21, 3240-3244.
15. Bose, R.; Zhang, X. The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp. Cell Res. 2009, 315, 649-658.
16. Sharma, S.V.; Bell, D.W.; Settleman, J.; Haber, D.A. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7, 169-181.
17. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA 1999, 96, 4592-4297.
18. Glick, R.D.; Swendeman, S.L.; Coffey, D.C.; Rifkind, R.A.; Marks, P.A.; Richon, V.M.; La Quaglia, M.P. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res. 1999, 59, 4392-4399.
19. Butler, L.M.; Agus, D.B.; Scher, H.I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H.T.; Rifkind, R.A.; Marks, P.A.; Richon, V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000, 60, 5165-5170.
20. Oyelere, A.K.; Chen, P.C.; Guerrant, W.; Mwakwari, S.C.; Hood, R.; Zhang, Y.; Fan, Y. Non-peptide macrocyclic histone deacetylase inhibitors. J. Med. Chem. 2009, 52, 456-468.
21. Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R.; Pazdur, R., FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007, 12, 1247-1252.
22. Grant, C.; Rahman, F.; Piekarz, R.; Peer, C.; Frye, R.; Robey, R.W.; Gardner, E.R.; Figg, W.D.; Bates, S.E. Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev. Anticancer Ther. 2010, 10, 997-1008.
23. Mwakwari, S.C.; Patil, V.; Guerrant, W.; Oyelere, A.K. Macrocyclic Histone Deacetylase Inhibitors. Curr. Top. Med. Chem. 2010, 10, 1423-1440.
24. Muller, S.; Kramer, O.H. Inhibitors of HDACs-Effective drugs against cancer? Curr. Cancer Drug Targets 2010, 10, 210-228.
25. Beckers, T.; Mahboobi, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Maier, T.; Ciossek, T.; Baer, T.; Kelter, G.; et al. Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases. Med. Chem. Comm. 2012, 3, 829.
26. Chandregowda, V.; Rao, G.V.; Reddy, G.C. One-pot conversion of 2-nitrobenzonitriles to quinazolin-4(3H)-ones and synthesis of gefitinib and erlotinib hydrochloride. Heterocycles 2007, 71, 39-48.
27. Bradner, J.E.; Mak, R.; Tanguturi, S.K.; Mazitschek, R.; Haggarty, S.J.; Ross, K.; Chang, C.Y.; Bosco, J.; West, N.; Morse, E.; et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc. Natl. Acad. Sci. USA 2010, 107, 12617-12622.
28. Kramer, O.H. HDAC2: A critical factor in health and disease. Trends Pharmacol. Sci. 2009, 30, 647-655.
29. Sun, Q.M.; Miao, Z.H.; Lin, L.P.; Gui, M.; Zhu, C.H.; Xie, H.; Duan, W.H.; Ding, J. BB, a new EGFR inhibitor, Exhibits prominent anti-angiogenesis and antitumor activities. Cancer Biol. Ther. 2009, 8, 1640-1647.